345 results about "Low-substituted hydroxypropylcellulose" patented technology

In order to provide a composition having a long gastroduodenal residence time and exhibiting an improved efficacy, is provided a gastrointestinal mucosa-adherent composition comprising an active ingredient and a material which swells a viscogenic agent capable of being viscous with water a (e.g. curdlan and/or a low-substituted hydroxypropylcellulose etc.).

The present invention relates to a compound salvia oral disintegrant tablet capable of being disintegrated quickly in oral cavity to release medicine. It composition includes the salvia root extract, notoginseng total saponin, borneol and excipient, and its disintegration time is within 40 sec, in which the excipient includes filling agent, disintegrant, glidant and corrective. Its filling agent is of microcrystalline cellulose, its dose is 40%-90% of total weight of the prescription, and the disintegrant is selected from sodium carboxymethylstarch, cross-linked carboxymethylcellulose sodium, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose, and its dose is 5%-25% of total weight of prescription.

The invention discloses benzene sulfonic acid levo-amlodipine pills and a preparation method thereof. On the basis of 1000 pills, the benzene sulfonic acid levo-amlodipine pill comprises 1-10g of benzene sulfonic acid levo-amlodipine, preferably 2.5g; 50-100g of lactose, preferably 67-87g and most preferably 80g; 5-55g of low-substituted hydroxy propyl cellulose, preferably 20-40g and particularly preferred 30g; 2-20g of crosslinked polyethylene ketopyrrolidine, preferably 5g; and 0.5-2.5g of magnesium stearate, preferably 1.5g. The benzene sulfonic acid levo-amlodipine pills have more than 95 percent of dissolution rate and good production stability.

The invention discloses a dispersible tablet of colloid pectin, which comprises (by weight ratio, in mg) colloid pectine bismuth 25-100 (by bismuth), filling agent 60-400, crumbling agent 42-280, flow aid 1-6, lubricant 0.25-5, the filling agent can be selected from lactose, white dextrine, pregelatine starch or/and starch. The crumbling agent can be selected from cross bonding polyvinylpyrrolidone, crystalline cellulose, cross-linked sodium carboxymethylstarch, low substituted methylcellulose propylene glycol ether, sodium carboxymethylstarch, the glidant can be selected from miropowdered silica gel, the lubricant can be selected from magnesium stearate or/and talcum powder.

The present invention relates to an orally disintegrating tablet containing (1) an active ingredient, (2) mannitol, (3) crystalline cellulose and (4) at least two kinds of particular ingredients selected from the group consisting of low-substituted hydroxypropylcellulose, cornstarch and carmellose, wherein the blending ratio of each ingredient relative to 100 wt % of the disintegrating tablet is (1) 0.01 to 50 wt %, (2) 20 to 86 wt %, (3) 10 to 30 wt %, and (4) 1 to 20 wt % for each particular ingredient and 3 to 60 wt % as the total of the particular ingredients to be blended, and an assembly of (3) crystalline cellulose to be blended has a bulk density of not more than 0.18 g/cm³, and can provide an orally disintegrating tablet having both suitable hardness and rapid disintegrability in oral cavity, which maintains orally disintegrability even under moist conditions, and hardness of not less than a predetermined level necessary for using in an automatic packaging machine.

The present invention relates to an oral disintegration tablet and its preparation method. It includes the medicinal active component and auxiliary material. Auxiliary material includes diluting agent and disintegrant, in which the diluting agent is mannite and lactose and the disintegrant is microcrystal cellulose, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone, the weight of disintegrant is less than 25% of total weight of the auxiliary material, the weight ratio of medicinal active component and auxiliary material is 1:2-75. Said disintegration tablet has enough hardness (strength).

The invention relates to a voglibose dispersible tablet and capsule and a preparation method thereof. The voglibose dispersible tablet comprises: 0.01-5 percent of voglibose, 1-99 percent of disintegrating agent, 0-98 percent of diluting agent; 0.5-20 percent of lubricant and fluidizer, 0.1-20 percent of bonding agent; wherein, the disintegrating agent is one or more selected from starch, modified starch, cellulose, microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, alginic acid and colloid magnesium aluminum silicate; the diluting agent is one or more selected from lactose, mannitol, sorbitol, sucrose, calcium sulfate, kaolin, dextrine and sodium chloride. The capsule preparation does not contain the bonding agent. The invention has the advantages that the voglibose dispersible tablet disintegrates swiftly and disperses evenly, the voglibose dispersible tablet can be disintegrated swiftly into fine particles and scattered evenly after being taken orally, which is beneficial for the dissolution and the absorption of the voglibose dispersible tablet with the short onset time. Disintegrated swiftly in three minutes; after being taken orally, the capsule shell quickly swells and splits, which conceals the discomfort caused by the capsule taken in mouth.

Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18-1.24, tablets that solely consist of the particles of a phosphate-binding polymer having an average particle size of no more than 400 μm, with at least 90% being occupied by particles no larger than 500 μm, and having a true specific gravity of 1.18-1.24 and a water content of 1-14%, or tablets that contain both the particles and crystalline cellulose and/or low substituted hydroxypropyl cellulose, and a process for producing such tablets. The phosphate-binding polymer can be formulated as tablets either alone or in combination with specified additives. Whichever the case, the tablets have satisfactory hardness, contain the active ingredient in high proportion, have high phosphate-binding capability and exhibit rapid disintegrability in an acidic to neutral region while having little sensitivity to the strength of agitation. The tablets are excellent pharmaceutical preparations that undergo reduced variations in bioavailability in spite of movements within the digestive tracts and pH changes.

The solid preparation of the present invention aims at providing a solid preparation superior in the stability during production and preservation even when a poorly water-soluble substance having a low melting point is contained in a large amount, and also superior in the disintegration property and release property of a poorly water-soluble substance having a low melting point, after oral administration, and is characterized by the following 1) to 3): 1) containing a poorly water-soluble substance having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, 2) a saccharide/cellulose weight ratio exceeding 2, and 3) a cellulose content of not less than 5 wt %.

The invention discloses ticagrelor tablets and a preparation method thereof and belongs to the technical field of medicines. According to the ticagrelor tablets disclosed by the invention, mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate are selected as auxiliary materials and are compounded with the raw material medicine ticagrelor tablets so as to obtain the ticagrelor tablets, and each auxiliary material and the raw material medicine are synergetic in the defined amount range, so that the dissolution rate of the prepared ticagrelor tablets is higher than that of the conventional commercially available tablets. Moreover, the ticagrelor tablets have the same dissolution behavior as the commercially available medicines, the ticagrelor tablets have good absorption effects, and the bioavailability of the ticagrelor tablets is improved. The ticagrelor tablets disclosed by the invention are small in impurity content and are stable in performance under high-temperature illumination conditions. The method for preparing the ticagrelor tablets disclosed by the invention is simple in process flow, easy to operate and implement and suitable for industrial popularization and application.

The invention provides a dual-phase capsule for preventing and treating chronic pelvic inflammation and a preparation method and a detection method thereof. The dual-phase capsule for preventing and treating chronic pelvic inflammation is prepared by extracting 20g of Chinese pulsatilla root, 20g of nutgrass galingale rhizome, 12g of twotooth achyranthes, 12g of Chinese atractylodes, 8g of amur corktree bark and 8g of selinum japenious seed serving as bulk pharmaceuticals, adding a proper amount of superfine silica powder and low-substituted hydroxypropyl cellulose, and adding 80 percent ethanol as a wetting agent. Aiming at the defects in the prior art, a preparation process of the dual-phase capsule for preventing and treating chronic pelvic inflammation is optimized, so that the curative effect of the dual-phase capsule on chronic pelvic inflammation is more remarkable. A systematic, complete and effective component identification and content determination method is established, so that the quality of the dual-phase capsule can be controlled effectively, and the clinical curative effect is ensured.

The invention relates to a nitroglycerin cavity (hypoglossis) disintegrating tablet and a preparation method which mainly adopts water-soluble excipient. When coming across saliva, a disintegrating tablet can be disintegrated rapidly and most of the excipient is dissolved, which can be absorbed into body to recycle by hypoglossis mucosa. The main indigent of the invention is nitroglycerin ethanol solution occupying 10 percent in weight, and the containing weight uses the mixture of lactose and xylitol in every 10g is 0.8 to 0.9ml. The excipient comprises microcrystalline cellulose 101, low-substituted hydroxypropyl cellulose, disintegrant, lactose, xylitol, alcoholic solution of PVP30 and magnesium stearate. The invention adopts a wet method of preparing particle and tablet, combines with blank particle method to mix the blank particles and the particles containing medicine after being made into particles, which changes the traditional method of spraying medicine layer to blank particles and raises the stability of medicine. The pressure of a tabletting machine is adjusted to 1 to 3kg and the disintegration of the pressed tablets is speeded up.

A tablet for epalrestat for suppressing the transmission speed decreasement of sciatic nerve and coccygeal nerve and the increasement of sorbitol in red cell and sciatic nerve is prepared from lactose, microcrystalline cellulose, low-substituent hydroxypropyl cellulose, carboxymethyl starch sodium magnesium stearate and epalrestat through sequential mixing, granulating, drying, coating and tabletting.

Provided are a solid dosage form comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising an enteric solid dispersion comprising a poorly soluble drug, an enteric polymer and a disintegrant, wherein the disintegrant is low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 [mu]m and a specific surface area measured by BET method of at least 1.0 m 2 /g. Moreover, provided is a method for producing a solid dosage form comprising an enteric solid dispersion, the method comprising steps of: spraying an enteric polymer solution in which a poorly soluble drug has been dispersed or dissolved, on a powder of low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 [mu] m and a specific surface area measured by BET method of at least 1.0 m 2 /g and serving as a disintegrant; and granulating the resultant; and drying.

The invention relates to a perampanel coated tablet pharmaceutical composition, in particular to a pharmaceutical composition in the form of tablets. The pharmaceutical composition comprises perampanel, an excipient, a disintegrating agent, a binder and a lubricant, wherein the excipient is selected from lactose, sucrose, glucose, corn starch, mannitol, sorbitol, starch, calcium hydrogen phosphate and the like, the disintegrating agent is selected from agar, calcium citrate, dextrin, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, carboxymethyl starch, carboxymethyl starch sodium and the like, the binder is selected from polyvinyl alcohol, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, hydroxy propyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, polyethylene glycol and the like, and the lubricant is selected from magnesium stearate, calcium stearate, talcum powder, polyethylene glycol, colloidal silicon dioxide and the like. The invention further relates to a preparation method and application of the composition. The pharmaceutical composition has excellent properties as described in the description.

The invention discloses a live-keeping transport box for aquatic products. The live-keeping transport box comprises a box body with an open top, wherein an oxygenating agent layer, a sponge layer and a pressing plate are sequentially arranged in the box body from bottom to top, a closed cavity is formed in the middle of the pressing plate, a cushion chamber is formed by the closed cavity, circulation holes which are uniformly distributed are formed in the top face of the pressing plate, capillary holes which are uniformly distributed are formed in the bottom face of the pressing plate, the circulation holes and the capillary holes are communicated with the cushion chamber, and an oxygenating agent in the oxygenating agent layer is prepared from the following ingredients in percentage by mass: 5-10% of vermiculite powder, 10-15% of microcrystalline cellulose, 2-5% of low-substitution hydroxypropyl cellulose, 2-5% of lactose and the balance of calcium peroxide. The live-keeping transport box for the aquatic products is simple in structure and convenient to transport; and the oxygenating agent is adopted to oxygenate water in the transport box, and a formula of the oxygenating agent is subjected to optimization and improvement, so that the oxygenating effect is good, the stress effect on the aquatic products is low, and thus the increase of the survival rate of the aquatic products is facilitated.

The present invention relates to a high-effective oral silibinin (SLB) slow-released preparation. Its composition includes (by mass component portion) 1 portion of silibinin, 1.5-2.5 portions of polyvidone-K30, 0.23-0.58 portion of hydroxypropyl methyl cellulose 4000cPa.S, 0.46-1.38 portions of low-substituted hydroxypropyl cellulose. Said invention adopts the combination of solid dispersion technique and slow-released hydrophilic gel skeleton technique to raise the dissolubility of silibinin.

The invention relates to a cefditoren pivoxil tablet. The tablet comprises a tablet core and a coating layer, wherein the tablet core contains amorphous cefditoren pivoxil, a filler, a disintegrating agent, a solubilizer and a lubricant, and the filler is a mixture of D-mannitol and beta-cyclodextrin and/or low-substituted hydroxy propyl cellulose. The cefditoren pivoxil tablet avoids the conversion of amorphous cefditoren pivoxil to crystals and has good disintegration and dissolve-out properties under four dissolve-out conditions, and the dissolve-out curve of the cefditoren pivoxil tablet is consistent with the dissolve-out curve of a listed product Meiact.

The invention discloses a preparation method of a berberine hydrochloride tablet, and the preparation method is applied to the field of pharmaceutical preparation. The berberine hydrochloride tablet consists of a tablet core and a coating material, wherein the tablet core consists of berberine hydrochloride and auxiliary materials, each tablet contains 300mg of the berberine hydrochloride, and the auxiliary materials contains one or a plurality of a filling agent, a disintegrating agent, a lubricant, a surfactant and a wetting agent; a coating layer consists of the coating material and water; the coating layer further contains a plasticizer or an antiadherent, wherein the filling agent contains one or a random composition of starch, lactose, pregelatinized starch and microcrystalline cellulose; the disintegrating agent contains one or a random composition of crosslinking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, sodium carboxymethyl starch, hydroxypropyl starch and low-substitution hydroxyl propyl cellulose; and the lubricant contains one or a random composition of aerosol, talc powder and magnesium stearate. The method is suitable for the large-scale and long-time production of production departments, and has the advantages of stable technology, no dependence on tablet machines, good particle liquidity and formation, controllable tablet weight difference, stable quality, high tablet core hardness, difficulty in wearing and coating suitability.

Disclosed is an asiabell polysaccharide tablet of asiabell effective ingredient, wherein the main ingredients include codonopsis pilosula polysaccharides 100-600 parts, the auxiliary materials include low substituted methylcellulose propylene glycol ether or crystalline cellulose 2-4 parts, and magnesium stearate 0.5-1.5 parts, cocoa powder or mannitol.

An instant solid preparation of gingko leaf extract is disclosed, which includes the dispersing tablet prepared by freeze drying, spray drying, or direct tabletting press and coating, tabletting press methods, and the oral disintegrating tablet prepared from gingko leaf extract, disintegrant, filler, adhesive, lubricant and flavouring.